Detailed price information for Solid Biosciences Inc (SLDB-Q) from The Globe and Mail including charting and trades.
Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
Milestone advances two-part study evaluating novel, locally administered gene therapy designed to increase anti-inflammatory ...
("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the ...
UniQure shares soared on positive AMT-130 Huntington's disease data, but plunged after the FDA reversed its stance on ...
Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...
The production of cell and gene therapies faces stringent regulatory requirements that demand the use of high-quality, animal ...
Azalea Therapeutics, Inc., a biotechnology company redefining precision genomic medicines in vivo, today announced its official launch and completion of $82 million in seed and Series A financing to ...
A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback